Life Sciences Voice

Life Sciences Voice Life Sciences Voice is the leading resource for life sciences executives to get crucial insights

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Lyell Immunopharma has entered a new licensing agreement that grants it access to a phase 1 CAR-T cell therapy designed ...
11/13/2025

Lyell Immunopharma has entered a new licensing agreement that grants it access to a phase 1 CAR-T cell therapy designed to treat colorectal cancer. Under the terms, the company will pay $40 million in cash and issue nearly 2 million shares to secure global rights to the program.

Phase 2 Trial Shows Promising ResultsEli Lilly and Company reported that its experimental amylin agonist, eloralintide, ...
11/12/2025

Phase 2 Trial Shows Promising Results

Eli Lilly and Company reported that its experimental amylin agonist, eloralintide, achieved up to 20.1% weight loss after 48 weeks in a phase 2 trial. Based on these results, the company plans to begin phase 3 studies next month as it expands its presence in the obesity drug market.

Tenaya Therapeutics announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its ongoing...
11/12/2025

Tenaya Therapeutics announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its ongoing trial evaluating TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, a rare inherited heart disorder characterised by abnormal thickening of the heart muscle. Following the announcement, shares of Tenaya declined by more than 20% in extended trading.

Phase 2 Study Shows Mixed Efficacy for CoramitugNovo Nordisk has released results from a midstage study evaluating coram...
11/12/2025

Phase 2 Study Shows Mixed Efficacy for Coramitug

Novo Nordisk has released results from a midstage study evaluating coramitug, its investigational therapy for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), showing a mixed outcome in efficacy measures.

Akeso has reported new data from its phase 3 HARMONi-A study indicating that ivonescimab, when added to chemotherapy, ca...
11/12/2025

Akeso has reported new data from its phase 3 HARMONi-A study indicating that ivonescimab, when added to chemotherapy, can extend survival in patients with previously treated EGFR-mutated nonsquamous non-small cell lung cancer (NSCLC). The results, presented at the 2025 Society for Immunotherapy of Cancer annual meeting, show that the treatment significantly lowered the risk of death compared with chemotherapy alone.

Harmony Biosciences has halted development of its cannabidiol gel candidate, ZYN002, for 22q11.2 deletion syndrome after...
11/11/2025

Harmony Biosciences has halted development of its cannabidiol gel candidate, ZYN002, for 22q11.2 deletion syndrome after the treatment failed to meet key efficacy goals in a late-stage study for fragile X syndrome.

Merck & Co. Secures Major Funding for Oncology PortfolioMerck & Co. announced deals that include a $150 million upfront ...
11/11/2025

Merck & Co. Secures Major Funding for Oncology Portfolio

Merck & Co. announced deals that include a $150 million upfront payment to gain full ownership of an early-stage program and a $700 million cash infusion to advance its late-stage cancer portfolio.

Sarepta Therapeutics Faces Setback in DMD TherapiesSarepta Therapeutics has been receiving challenges one after another....
11/11/2025

Sarepta Therapeutics Faces Setback in DMD Therapies

Sarepta Therapeutics has been receiving challenges one after another. The company announced that its exon-skipping therapies, Vyondys 53 and Amondys 45, did not significantly improve motor function in patients with Duchenne muscular dystrophy. However, Sarepta will pursue the treatments for full FDA approval, notifying its investors of its intentions during its third-quarter earnings call.

FDA Rejects Troriluzole, Biohaven Pivots StrategyThe FDA has turned down Biohaven’s bid to secure approval for its neuro...
11/11/2025

FDA Rejects Troriluzole, Biohaven Pivots Strategy

The FDA has turned down Biohaven’s bid to secure approval for its neurological disease treatment, prompting the company to restructure priorities and slash annual R&D spending by 60%.

The oncology biotech Bolt Biotherapeutics, Inc. has reduced its staff by half again in its second downsizing announcemen...
10/08/2025

The oncology biotech Bolt Biotherapeutics, Inc. has reduced its staff by half again in its second downsizing announcement in two years as the firm held back a readout of its lead immunotherapy.

Italy’s Chiesi Group and U.S.-based Arbor Biotechnologies have entered a global research and licensing collaboration val...
10/08/2025

Italy’s Chiesi Group and U.S.-based Arbor Biotechnologies have entered a global research and licensing collaboration valued at more than $2 billion. The agreement, announced on October 6, focuses on the development and commercialization of Arbor’s gene therapy candidate ABO-101 for the rare liver disease primary hyperoxaluria type 1 (PH1).

Already having changed the path of its rare disease gene therapy toward a hoped-for FDA approval, Rocket Pharmaceuticals...
10/08/2025

Already having changed the path of its rare disease gene therapy toward a hoped-for FDA approval, Rocket Pharmaceuticals has now cancelled the mission altogether.

Address

New York, NY

Website

Alerts

Be the first to know and let us send you an email when Life Sciences Voice posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Life Sciences Voice:

Shortcuts

Share

Category